Blinkist Chooses Monte Carlo to Deliver More Reliable Data Pipelines Through Data Observability
20.5.2021 14:00:00 EEST | Business Wire | Press release
Monte Carlo, the data reliability company, today announced Berlin-based microlearning app Blinkist has selected Monte Carlo to achieve more reliable data through data observability.
As a high-growth company with over 16 million users worldwide, Blinkist leverages paid performance marketing to fuel customer acquisition — and those channels rely on accurate behavioral data to optimize campaign spend. Like many companies today, Blinkist’s data engineering teams have been challenged by broken pipelines, missing or inaccurate data, and a subsequent lack of trust in data across their organization.
Monte Carlo is an end-to-end Data Observability Platform that enables data teams at companies like Blinkist to seamlessly monitor the health of their data assets by applying the proven principles of application observability to data. Simultaneously, Monte Carlo provides CDOs and other data stakeholders with a holistic view of their company’s data health and reliability across critical business use cases.
“For Blinkist, having trustworthy and reliable data is foundational to the success of our business. When the pandemic hit, real-time data became even more crucial to understand the reality of our audience’s daily lives,” stated Gopi Krishnamurthy, Director of Engineering at Blinkist. “Any inaccuracies were both timely and costly; our team was spending 50% of their time on fixing these. Monte Carlo enabled us to adopt data reliability engineering principles and increased transparency about data health across the company.”
After onboarding Monte Carlo, the platform’s automated monitoring and intelligent alerting has already allowed Blinkist data engineers to reclaim up to 120 hours per week and enabled them to focus on innovation and product, rather than firefighting data issues. The Monte Carlo platform also helps their team build organizational trust in data by providing visibility into issues, and delivers the confidence Blinkist engineers need to implement and maintain data-specific Service Level Agreements (SLAs).
With more reliable and accurate data in place, Blinkist marketers can now make swift decisions to improve targeting and performance, leading to higher overall revenue for the company.
“We are thrilled that Blinkist has chosen Monte Carlo as their data reliability partner,” stated Barr Moses, CEO and co-founder of Monte Carlo. “In today’s environment, data is a company’s most critical asset. Our team is proud to help Blinkist unlock the potential of their data.”
About Monte Carlo
As businesses increasingly rely on data to drive better decision making, it’s mission-critical that this data is accurate and reliable. Billed by Forbes as the New Relic for data teams and backed by Accel and GGV, Monte Carlo solves the costly problem of broken data through their fully automated, SOC-2 certified data observability platform.
About Blinkist
Blinkist is a Berlin-based microlearning app that has grown to over 16 million users worldwide since its launch in 2012. A pioneer in new audio learning formats, their library of over 4,000 titles-turned-Blinks includes topics like society and culture, wellness, parenting, leadership, and more. Blinkist products are curated by editorial experts in collaboration with high-profile, expert creators across a wide variety of fields. Their formats include Blinks, Audiobooks, and now, Shortcasts, accessible across all iOS and Android mobile devices.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210520005096/en/
Contact information
Molly Vorwerck
Monte Carlo
mvorwerck@montecarlodata.com
949-230-4860
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
